17 Capital Partners’s AstraZeneca AZN Stock Holding History

17 Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Buy	1,472 +45	+3%	+$8.46K	0.13%	159
2026 Q1	$281K	Buy	1,427 +151	+12%	+$29.1K	0.14%	156
2025 Q4	$235K	Sell	1,276 -29	-2%	-$5.09K	0.12%	152
2025 Q3	$200K	Buy	+1,305	New	+$198K	0.11%	144

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

17 Capital Partners's AZN Position: Q2 2026 in Review

17 Capital Partners increased its AstraZeneca (AZN) stake by 3.2% in Q2 2026, buying an estimated $8.46K and bringing the position to 1,472 shares worth $279K. The position accounts for 0.13% of the portfolio, ranked #159.

17 Capital Partners first reported a position in AZN in Q3 2025 and has held it in 4 quarters since. The position peaked at $281K in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

17 Capital Partners held 1,472 shares of AstraZeneca worth $279K as of Q2 2026.
17 Capital Partners bought 45 AstraZeneca shares in Q2 2026, an estimated $8.46K.
AstraZeneca made up 0.13% of 17 Capital Partners's portfolio in Q2 2026, its #159 holding.
17 Capital Partners first reported a position in AstraZeneca in Q3 2025 and has held it in 4 quarters since.
17 Capital Partners's AstraZeneca position peaked at $281K in Q1 2026.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.